Related Experiment Video

Updated: Aug 14, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo

S K Richards1, L E Parton, I Leclerc

  • 1Richard Bright Renal Unit, Southmead Hospital, Bristol BS10 5NB, UK.

The Journal of Endocrinology
|November 19, 2005
PubMed

Insights

Activating AMP-activated protein kinase (AMPK) impairs beta-cell function and survival in islet transplantation. Inhibiting AMPK may improve graft function and glycemic control in type 1 diabetes treatment.

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Transplantation Biology

Background:

  • Islet transplantation for type 1 diabetes faces challenges due to functional beta-cell loss post-transplant.
  • AMP-activated protein kinase (AMPK) influences insulin secretion in vitro, but its in vivo role in islet graft function is unclear.

Purpose of the Study:

  • To investigate the impact of adenovirus-mediated AMPK modulation on islet graft function and beta-cell survival in vivo.
  • To determine if targeting AMPK activity can enhance islet transplantation outcomes.

Main Methods:

  • Adenovirus-mediated overexpression of constitutively active AMPK (AMPK CA) or dominant-negative AMPK (AMPK DN) in isolated mouse and rat islets.
  • Assessment of glucose-stimulated insulin secretion and glucose oxidation in vitro.
  • Evaluation of beta-cell apoptosis using TUNEL assay.
  • Transplantation of modified islets into streptozotocin-diabetic mice to assess in vivo graft function and glycemic control.

Main Results:

  • Overexpression of AMPK CA significantly inhibited glucose-stimulated insulin secretion and glucose oxidation in isolated islets.
  • AMPK CA activation led to increased beta-cell apoptosis (TUNEL-positive cells).
  • Transplantation of AMPK CA-expressing islets resulted in poorer glycemic control compared to control or AMPK DN-expressing islets.

Conclusions:

  • AMPK activation negatively affects beta-cell function and survival in the context of islet transplantation.
  • AMPK represents a potential therapeutic target to improve beta-cell function and graft survival in islet transplantation for type 1 diabetes.

More Related Videos

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...